Amarin Corp Plc (AMRN)

[KCSVEN]

This is a solid shot at the FDA if Anchor is denied

" We see 5% chance AdComm will demand REDUCE-IT data preapproval,
95% AdComm is fine with it as a Phase 4 commitment.
REDUCE-IT will not yield data until 2016-2017. In the unlikely event
common sense and any value placed on practical drug development
explodes, we think AMRN shares will go much lower."